A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. (Q53359316)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. |
scientific article |
Statements
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. (English)
Branimir I Sikic
Lynn Hartmann
Ranjana Advani
Prema Peethambaram
Bert L Lum
George A Fisher
Harry J Long
Joanne Halsey
Jon T Holmlund
Andrew Dorr
1 January 2004
100
2
321-326